Biorelate uses AI to provide to curate masses of data from biomedical knowledge databases and published literature to pharmaceutical and biotechnology companies and academic institutes. Biorelate uses existing knowledge to help scientists solve difficult biomedical challenges, enabling smarter and faster research and development.
I’m absolutely thrilled to have Maven and the MTTA on board for this journey and to have the amazing Catapult Ventures team commit further.
Dr Daniel Jamieson
CEO of BioRelate
Founded in 2014, Biorelate is a start-up and has done particularly well to generate revenue so early into its existence. The Company’s technology combines natural language processing and AI with human expert curation to generate highly relevant output from unstructured big data. Uses of Biorelate’s technology include curation and exploration of unused sources of knowledge of molecular mechanisms for drug discovery, tracking specific biomedical developments, expertise sourcing and competitive intelligence.
Having spent a year in a beta phase commercialising the founder’s PhD work at the University of Manchester on big data computational analysis, the business is experiencing strong demand for its services, including a recent collaboration deal signed with an AIM listed drug-discovery specialist. CEO Daniel Jamieson has a background in biology and bioinformatics and founded the business while completing his PhD at the University of Manchester after successfully prototyping a highly efficient and accurate method of disease curation.
Biorelate will use the funding to grow the team and to develop its product offering, including three new SaaS products.
Could NPIF Maven Equity Finance help fund your growth journey?
If you’re running a business that’s looking to grow, we’d love to hear from you. Feel free to give us a call to find out more about our flexible funding solutions:
0191 731 8595
Subscribe for email updates
Keep up-to-date with all the latest news and insights from Maven,
including new investments, events and our blog.